Madrigal Pharmaceuticals, Inc.

MDGL08 Dec 2024
Healthcare
$310.96
+0.02 (+2.49%)
Lowest Today
$310.96
Highest Today
$321.99
Today’s Open
$310.96
Prev. Close
$313.05
52 Week High
$368.29
52 Week Low
$168.25
To Invest in Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

Healthcare
MDGL08 Dec 2024
+0.02 (+2.49%)
1M
3M
6M
1Y
5Y
Low
$310.96
Day’s Range
High
$321.99
310.96
52 Week Low
$168.25
52-Week Range
52 Week High
$368.29
168.25
1 Day
-
1 Week
+0.81%
1 month return
-8.46%
3 month return
+34.35%
6 month return
+25.74%
1 Year return
+54.13%
3 Years return
+313.56%
5 Years return
+173.55%
10 Years return
-
Institutional Holdings
HHG PLC
11.36
Paulson & Company Inc
9.36
venBio Select Advisor LLC
9.3
RTW INVESTMENTS, LLC
9.14
Baker Bros Advisors LP
9.05
Vanguard Group Inc
8.41
BlackRock Inc
6.54

Market Status

Fundamentals
Market Cap
6997.65 mln
PB Ratio
9
PE Ratio
0
Enterprise Value
6118.16 mln
Total Assets
640.55 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Organisation
Madrigal Pharmaceuticals, Inc.
Employees
376
Industry
Biotechnology
CEO
Mr. William J. Sibold
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step